Scholar Rock Holding Corporation (SRRK)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
SRRK price, last 12 months
Key stats
- Previous close
- $48.61
- Open
- $48.80
- Day range
- $48.19 – $49.47
- 52-week range
- $27.07 – $61.76
- Volume
- 1.4M
- Avg volume (20 days)
- 2.1M
- Market cap
- $5.9B
Performance
Technicals and fundamentals
About Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $5.9B